Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

NCT02981745 is registered in ClinicalTrials.gov with Centaurus Biopharma Co., Ltd. as lead sponsor.

NCT NCT02981745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02981745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Lead sponsor
Centaurus Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 1, 2017
Completion date
December 31, 2018
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicle centre lymphoma diffuse, mantle zone lymphoma refractory/recurrent, relapsed or refractory b cell non-hodgkin lymphoma, waldenstrom's macroglobulinemia